Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 7/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL3278618 | 0.83 | DNMT1 (0.91) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20772029 | 0.82 | DNMT1 (0.97) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 0.81 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20220024965-A1 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | OTSUKA PHARMA CO LTD (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20220016033-A1 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS | OTSUKA PHARMA CO LTD (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11058705-B2 | Drug formulations | ASTEX PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2021-05-20 | — | — | US | disclosed |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10858386-B2 | Drug compound and purification methods thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| CN-108635367-B | Decitabine derivative formulations | 阿斯泰克斯制药公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2014134355-A1 | DRUG COMBINATIONS | ASTEX PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2750768-A1 | DECITABINE DERIVATIVE FORMULATIONS | Astex Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8461123-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013033176-A1 | DECITABINE DERIVATIVE FORMULATIONS | ASTEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7700567-B2 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | SUPERGEN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1943264-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SuperGen, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-11058705-B2 | Drug formulations | MCL1, DNMT3A, TET2 | DNMT1 11/4885ADRB1 4772/4885LMNA 1230/4885 |
| US-10858386-B2 | Drug compound and purification methods thereof | SRMS, TREH, SYMPK | DNMT1 3999/4885ADRB1 2940/4885LMNA 4016/4885 |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | DNMT1 4571/4885ADRB1 932/4885LMNA 1945/4885 |
| US-20220024965-A1 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | SRMS, TREH, SYMPK | DNMT1 3999/4885ADRB1 2940/4885LMNA 4016/4885 |
| US-20220016033-A1 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS | TREH, DUSP5, SLC5A11 | DNMT1 4829/4885ADRB1 2249/4885LMNA 4045/4885 |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20210147466-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF | UNG, SAMHD1, ALKBH1 | DNMT1 24/4885ADRB1 4319/4885LMNA 686/4885 |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | DCTD, DNMT3B, NT5C3B | DNMT1 8/4885ADRB1 3994/4885LMNA 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.